A medical institution has applied for permission to carry out a clinical trial that will attempt to use embryonic stem cells to treat babies with a severe liver condition, which would be a first for Japan.
The National Center for Child Health and Development plans to commercialize the process around 2020 to treat babies with livers that are unable to detoxify ammonia, one of the compounds resulting from the body’s processing of protein.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.